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Ablative radioiodine therapy is the standard treatment for
thyroid carcinoma, but as 131I is predominantly cleared by
renal excretion, its clearance will be reduced in patients with
chronic kidney disease, particularly in anuric patients on
dialysis. The high dose of radioactivity used in the procedure
results in an increased risk of radioactive exposure to the
patient, the dialysis staff, and the machinery. Here, we
describe how to successfully hemodialyze patients with
chronic kidney failure requiring ablative 131I therapy for
thyroid cancer while minimizing risks to the patient and
dialysis staff. With appropriate training, hemodialysis
treatments can be safely delivered to patients receiving
radiotherapy.
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Although solid organ malignancy, in general, is not increased
in end-stage kidney failure patients treated by regular dialysis
compared with the general population,1 patients can develop
internal malignancies, which may require chemotherapy.
Ablative radioiodine (131I) therapy is the standard
treatment for thyroid carcinoma, and 131I is predominantly
cleared by renal excretion, but clearance will be reduced in
patients with chronic kidney disease and, in particular, anuric
patients established on dialysis. As the dose of radioactivity is
designed to be ablative, this potentially could result in an
increased risk of radioactive exposure to the patient, the
dialysis staff involved, and the dialysis machine.
Only a few centers in the UK have both the appropriate
European Union license for both providing and disposing of
this therapeutic radioactive isotope,2 in combination with
appropriate hemodialysis facilities.
131Iodine is predominantly a beta radiation emitter, and
thus there is a potential substantial risk of radiation exposure
to the dialysis staff, due to both the close proximity of
the staff to the patient and the contact time, including the
preparation of the hemodialysis machine, needling the fistula,
patient connection, and then monitoring of the hemodialysis
treatment.
We reviewed our clinical practice for treating such dialysis
patients. A multiprofessional team of renal, oncology,
radiation protection, and projects department staff was
assembled to identify the risks to all concerned. We report
our experience of how to minimize the potential risks, and
provide patients with successful 131I ablative therapy.
RESULTS
After a trial hemodialysis session, a standard clinical ablative
131I dose of 3000 MBq (megabecquerels) was administered
and the patient was nursed in isolation in his or her room,
with staff protected by lead shields.
On the third day after admission, the first 4 h hemodialysis
session took place some 39 h after radioiodine administra-
tion, when the radioactivity detected was 38 mSv and
11.1 mSv h1, at a distance of 1 and 2 m, respectively, from
the patient. Once the machine had been checked and
prepared, it was transferred from the shower room to the
patient’s room by the technician (Figure 1), and the dialysis
nurse connected the patient to the machine by inserting two
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needles into a forearm fistula. Once stabilized on dialysis, the
nurse left the room, and returned at regular intervals to check
pulse, blood pressure, and machine blood volume, on-line
clearance, and access monitoring. The patient had a buzzer
alarm for safety. As expected, patient radioactivity fell during
dialysis (Figure 2). Following dialysis, the hemodialysis
machine was put into an endless rinse mode to remove any
contaminating radioactive material. After 1 h, the radio-
activity level measured in the drain line was minimal, and no
different to background. The dialysis machine was then
moved back to the shower room and put into a heat disinfect
mode for 40 min.
The hemodialysis treatment was then repeated, 2 days
later, when the radioactivity was much less (Figure 2). The
patient was discharged the following day, as the radioactivity
had returned to background levels, to return to normal
outpatient hemodialysis.
The dialysis nurses and dialysis technicians wore finger
and waist dosimetry devices. When these were subsequently
read, the amount of radiation exposure was below the
threshold level of detection of both these monitors
(o100 mSv). As these standard devices cannot be read
instantaneously, health-care workers also carried real-time
recorders, and the results are set out in Table 1.
DISCUSSION
The key management is to provide the patient with 131I
radioablative therapy and yet to minimize radioactive
exposure to health-care workers (Table 2). It was impracti-
cable to move the radioactive patient to the dialysis center, so
dialysis had to be brought to the patient. This required
installing potable (drinking) water, to comply with home
hemodialysis water installations, and then providing suitable
water of chemical and microbacteriological quality.3–5 The
predicted radiation exposure to the dialysis nursing staff was
230 mSv. However, by providing radiation protection training,
and having one preradioablative hemodialysis session, in
which the staff wore appropriate clothing, and connected and
disconnected the patient, with the lead shields in place,
reduced the subsequent maximum radiation exposure to
12 mSv (approximately equivalent to half a chest X-ray;
Table 3). Staff members were equipped with extremity as well
as whole body monitoring, as exposure to b irradiation is
dependent upon distance from the radiation source The
cumulative finger and truncal exposure was below the level of
detection of these monitors (o100 mSv). The instantaneous
radiation exposure dose recorded by the dialysis nurse
performing the first hemodialysis treatment is approximately
equivalent to 5 days worth of exposure to the natural
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Figure 1 | Schematic plan of section of oncology ward. The
dialysis machine was prepared in the adjacent shower room—
shower room 1 using a potable water supply. The dialysis machine
and portable reverse osmosis unit were then moved into the
patient’s room and connected to a potable water supply and




























Figure 2 | Fall in 131I radioactivity emitted following a
standard clinical ablative dose of 3000 MBq, as measured 1-m
distance from both our example hemodialysis-dependent
patient and cancer patients with normal renal function.
Table 1 | Radioactive doses recorded, using the real-time
dose meter monitor (Bleeper Sv, Bartec Technology,
Camberley, Surrey, UK), from dialysis staff
Dialysis Dialysis staff Time (min) Radiation dose (lSv)
1st dialysis Nurse 1 28 12
Technician 1 28 7
2nd dialysis Nurse 2 30 3
Technician 2 18 0
Time refers to time spent in the patient’s room.
Table 2 | Anticipated problems of administering 131I to a
hemodialysis patient
Potential problem Risk of radiation exposure
Reduced 131I clearance Patient
Dialysis staff exposure Dialysis nurse
Dialysis assistant
Machine contamination Dialysis technician
Blood spills Nursing staff
Cleaning staff
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background radioactivity in London, and approximately less
than half that with a routine chest X-ray (Table 3), and so was
substantially less than that of previous reports.7 The standard
finger and truncal irradiation monitoring devices do not
provide an instantaneous assessment of radiation exposure,
but provide an assessment of total exposure. We therefore
suggest the use of an additional electronic dose meter for
real-time monitoring, so that in the event of a radioactive
spill, immediate assessment of radioactive exposure can
be readily made and, if necessary, medical personnel can be
promptly substituted.
Time spent in the immediate vicinity of the patient was
minimized, by preparing the dialysis machine in the adjacent
shower room, and then transferring it into the patient’s
room. Once the patient was stabilized on dialysis, the nurse
and technician left the room. The nurse then returned to
perform routine observations, and then at the end of the
session to disconnect the patient. The dialysis machine was
endlessly rinsed, until the radioactivity in the dialysate waste
had returned to baseline, and then moved and stored in the
shower room, until the second dialysis session. To reduce
individual staff radiation exposure, a second dialysis nurse
and dialysis technician supervised the second treatment.
Other centers have used different dialysis nurses to connect,
supervise, and then disconnect the patient during the dialysis
session, so as to reduce individual exposure.8
The dialysis machine was rinsed in the patient’s room,
until dialysate and machine radioactivity had returned to
background levels, and then disinfected as per standard.
Following rinsing and disinfection after the second dialysis,
the dialysis machine was subsequently returned to the
outpatient dialysis center for general patient usage, as no
excess radioactivity could be detected.
This hemodialysis patient received calculated radiation
doses of approximately 168 Gray (Gy) to the thyroid and
396 Gy to the bone marrow, compared with the standard
doses of 69 Gy to the thyroid and 165 Gy to the bone marrow,
respectively, to patients with normal renal function. The
increase dose was due to the reduced clearance of 131I in the
end-stage kidney failure patient, even though 131I was
effectively cleared by hemodialysis9 Excessive doses of ablative
131I have not been shown to provide additional irradiation of
the thyroid cancer, but they rather increase radiation
exposure to the bone marrow.9,10 However, this potential
excessive radiation exposure to bone marrow is derived from
mathematical models rather than clinical studies, as some
70% of radioactivity is taken up into the thyroid gland, and
in patients with normal renal function, rapid renal excretion
prevents toxic bone marrow uptake. However, in patients
with end-stage renal failure, particularly those who are
anuric, potentially up to 30% of the radioactive dose could be
taken up into other tissues including the bone marrow. To
prevent such potential over dosage, some centers have
recommended a dosage reduction, varying from as low as
18% to up to 50%.10,11 However, too large a reduction could
potentially result in a failure to deliver a radioablative dose of
131I. In the illustrative case described, the patient received a
standard dose of 3000 MBq. An alternative would be to
perform an earlier hemodialysis session if the patient
radioactivity detected was much greater than expected, to
help increase 131I removal.12 This would be important in
those cases when larger doses of ablative radiotherapy
(43000 MBq) are used.
Thus, with careful thought and appropriate training,
hemodialysis treatments can be safely delivered to radioactive
patients. The dialysis staff found the pretreatment dialysis
session very instructive, by practicing connecting the patient
to and disconnecting from the dialysis machine, while
wearing protective clothing and working behind the lead
shields.
MATERIALS AND METHODS
It was quickly realized that the risks to other patients, visitors, and
staff could not be adequately controlled if the patient were to be
moved from the oncology ward, after the 131I treatment, to the
outpatient hospital dialysis unit. Although the oncology ward had
the appropriate license for administering and disposing of 131I, there
were no facilities for routine hemodialysis treatments.
It was not practical to provide dialysis quality water3 to the
oncology ward, so a potable (drinking) water supply, protected by
two nonreturn valves in series to comply with UK regulations,4 was
installed into the bathroom leading from patient room 19 (Figure 1)
and also to the small shower room close by. Our stand-alone
intermittent hemodialysis water treatment system consists of two
(600 mm 75 mm) powdered, activated carbon (2 mm) filters in
series (KX Industries, LP. Connecticut, USA), a single patient reverse
osmosis monitor (WRO 100, Gambro AB, Lund, Sweden), and a
hemodialysis machine (4008H Fresenius Medical Care FMC, Bad
Homberg, Germany) fitted with an inline ultrafilter (Diasafe, FMC,
Bad Homberg, Germany). Such a water treatment setup has been
shown by our Dialysis Technical Services team to provide dialysis
fluid of an appropriate chemical and microbiological quality.3,5 A
drain line was also fitted to allow contaminated dialysate to enter the
approved waste drain in the room.
Iodine131 is mainly a beta radiation emitter and the best way to
minimize any exposure risks to nursing and allied medical staff is to
reduce the amount of close contact time with the patient (Table 2).
To help achieve this, the adjacent shower room (Figure 1) was used
as a preparation area, so that the reverse osmosis and hemodialysis
Table 3 | Comparative radiation exposure with radiological
investigations and risk of developing a malignancy due to
radiation exposure6
Procedure Effective dose (mSv) Risk per million
Knee X-ray 0.003 0.15
Chest X-ray 0.02 1.0
Pelvis X-ray 0.7 35
Lumbar spine X-ray 1.2 60
Tc-99m bone scan 3.0 150
Barium enema 7.2 360
CT scan abdomen 10 500
International air flight 8283 km 0.02 1
Annual natural radiation in UK 2.2 110
Technetium-labeled (Tc-99m) bone scan.
CT, computerized tomographic scan; UK, United Kingdom.
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machine could be set up and put through mandatory disinfection,
functional testing, and then lined and primed, physically away from
the patient. The hemodialysis machine could then be power-failed,
by disconnection of the power supply, moved into the patient’s
room, and then reconnected to the electrical supply. As the dialysis
machine has a battery back-up system, it reverts to the previous
state, without the necessity to repeat the setup cycle, allowing
prompt patient connection.
As with any electrical or mechanical equipment, there is a risk of
a technical fault occurring,13 and in the worst-case scenario—a
machine failure. A spare hemodialysis machine, already primed and
prepared, was kept in the dialysis unit on standby.
All staff to be involved in providing hemodialysis treatment to
the patient were given appropriate radiation protection training. To
minimize staff exposure, all staff wore theater scrub clothing, rather
than their usual hospital uniforms and/or clothing, and then
appropriate protective clothing (overshoes, gloves, and apron). Two
lead shields were placed in the room, a larger 5-cm-thick shield at
the entrance to the room, primarily designed to decrease the dose
rates outside the room to acceptable levels, and a smaller bedside
shield, for the nursing staff to work behind.
To help with the training of the staff, the patient had one
hemodialysis treatment in the room, before the administration of
131I. The dialysis nurse, with the help of the technical staff,
connected the patient to the machine. This took about 5–7 min and
was carried out behind a lead protection panel, and all staff wore
protective equipment and radiation monitoring devices, including
an electronic dose meter for real-time monitoring (Bleeper Sv,
Bartec Technology, Camberley, Surrey, UK). Besides whole body and
extremity radiation monitors, staff also wore finger monitors, as the
blood lines would be radioactive, and potentially there would be
increased risk of radiation exposure while connecting the patient to
and disconnecting the patient from the dialysis machine (Global
Dosimetry Solutions, Fountain Valley, CA, USA).
Following completion of the dialysis treatment, the machine was
rinsed for approximately 60 min and checked for radioactivity, and
once down to background activity, it was returned to the shower
room (Figure 1). All dialysis disposables were left in the patient’s
room in a special bin and removed by the radiation protection team.
In case of blood spills or dialysate leaks, the radiation protection
team were available on standby to help with decontamination.
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